184 related articles for article (PubMed ID: 6955072)
1. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
Zenebergh A; Baurain R; Trouet A
Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
[TBL] [Abstract][Full Text] [Related]
2. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
[No Abstract] [Full Text] [Related]
3. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
Zenebergh A; Baurain R; Trouet A
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):115-21. PubMed ID: 6537910
[TBL] [Abstract][Full Text] [Related]
4. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
5. Cellular accumulation and disposition of aclacinomycin A.
Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
[TBL] [Abstract][Full Text] [Related]
6. Cytofluorescence localization of anthracycline antibiotics.
Egorin MJ; Clawson RE; Cohen JL; Ross LA; Bachur NR
Cancer Res; 1980 Dec; 40(12):4669-76. PubMed ID: 6934029
[No Abstract] [Full Text] [Related]
7. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
8. [Effects of aclacinomycin B on biological macromolecular contents and synthesis of L1210 cells].
Li ZR; Feng JB; Liang F; Zeng SX; Han R
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Jun; 6(3):174-8. PubMed ID: 6241042
[No Abstract] [Full Text] [Related]
9. Chemical modification of anthracycline antibiotics. I. Demethoxycarbonylation, 10-epimerization and 4-o-methylation of aclacinomycin A.
Tanaka H; Yoshioka T; Shimauchi Y; Matsuzawa Y; Oki T; Inui T
J Antibiot (Tokyo); 1980 Nov; 33(11):1323-30. PubMed ID: 6941951
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
Meriwether WD; Bachur NR
Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells.
Ando S; Nakamura T; Kagawa D; Ueda T; Nishimura T; Kubo A; Tsutani H; Sasada M; Uchino H
Cancer Treat Rep; 1986 Jul; 70(7):835-41. PubMed ID: 3459574
[TBL] [Abstract][Full Text] [Related]
12. DNA-binding characteristics of aclarubicin as compared with daunorubicin and doxorubicin.
Ando S; Kamiya K; Yoshimura T; Tsutani H; Ueda T; Uchida M; Nakamura T; Uchino H
Anticancer Res; 1988; 8(3):409-15. PubMed ID: 3164610
[TBL] [Abstract][Full Text] [Related]
13. Production of new anthracycline antibiotics 1-hydroxy-oxaunomycin and 6-deoxyoxaunomycin by limited biosynthetic conversion using a daunorubicin-negative mutant.
Yoshimoto A; Johdo O; Tone H; Okamoto R; Naganawa H; Sawa T; Takeuchi T
J Antibiot (Tokyo); 1992 Oct; 45(10):1609-17. PubMed ID: 1473988
[TBL] [Abstract][Full Text] [Related]
14. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
15. Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
Egorin MJ; Clawson RE; Ross LA; Bachur NR
Cancer Res; 1980 Jun; 40(6):1928-33. PubMed ID: 7371027
[No Abstract] [Full Text] [Related]
16. New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.
Oki T; Takeuchi T; Oka S; Umezawa H
Recent Results Cancer Res; 1981; 76():21-40. PubMed ID: 6940212
[No Abstract] [Full Text] [Related]
17. Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.
Londos-Gagliardi D; Baurain R; Robert J; Aubel-Sadron G
Cancer Chemother Pharmacol; 1982; 9(1):45-8. PubMed ID: 6958392
[TBL] [Abstract][Full Text] [Related]
18. Preparation of 4- and 6-O-methyl-aclacinomycin derivatives and their antitumor activities.
Tanaka H; Yoshioka T; Shimauchi Y; Matsushita Y; Matsuzawa Y; Oki T; Inui T
J Antibiot (Tokyo); 1981 Jul; 34(7):905-8. PubMed ID: 7287594
[No Abstract] [Full Text] [Related]
19. Cellular pharmocodynamics of several anthrocycline antibiotics.
Bachur NR; Steele M; Meriwether WD; Hildebrand RC
J Med Chem; 1976 May; 19(5):651-4. PubMed ID: 1271407
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.
Skovsgaard T
Eur J Haematol Suppl; 1987; 47():7-20. PubMed ID: 3552720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
